Drug design and delivery最新文献_第9页

Pharmacokinetic evaluation of indomethacin nanocapsules. 吲哚美辛纳米胶囊的药动学评价。

Drug design and delivery Pub Date : 1989-06-01

V Andrieu, H Fessi, M Dubrasquet, J P Devissaguet, F Puisieux, S Benita

引用次数: 0

Effect of limonene and related compounds on the percutaneous absorption of indomethacin. 柠檬烯及相关化合物对吲哚美辛经皮吸收的影响。

Drug design and delivery Pub Date : 1989-06-01

H Okabe, K Takayama, A Ogura, T Nagai

引用次数: 0

Drug prospects in osteoarthritis. 骨关节炎的药物前景。

Drug design and delivery Pub Date : 1989-06-01

H A Bird

引用次数: 0

The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. 一种新的双氯芬酸钠缓释形式的人体内药代动力学。

Drug design and delivery Pub Date : 1989-06-01

H Mascher

引用次数: 0

Effect of cyclohexanone derivatives on in vitro percutaneous absorption of indomethacin. 环己酮衍生物对吲哚美辛体外经皮吸收的影响。

Drug design and delivery Pub Date : 1989-06-01

Q Danyi, K Takayama, T Nagai

引用次数: 0

The effect of substituted aminoalkylaminoanthraquinones on eukaryotic cells. 取代氨基烷基氨基蒽醌对真核细胞的影响。

Drug design and delivery Pub Date : 1989-06-01

J Katzhendler, G Bar-Ad, M Haran, K F Gean, Z Tashma, I Ringel, A Ramu, U Bachrach

引用次数: 0

The challenge of drug discovery. 药物发现的挑战。

Drug design and delivery Pub Date : 1989-05-01

D Jack

引用次数: 0

Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate. 水杨酸钠或辛酸钠对空心栓剂庆大霉素直肠吸收的促进作用。

Drug design and delivery Pub Date : 1989-05-01

Y Matsumoto, Y Watanabe, T Tojima, R Murakoshi, C Murakami, M Matsumoto

{"title":"Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate.","authors":"Y Matsumoto, Y Watanabe, T Tojima, R Murakoshi, C Murakami, M Matsumoto","doi":"","DOIUrl":"","url":null,"abstract":"The absorption of gentamicin (GM) from the rectum of rabbits after coadministration of GM (60 mg) and sodium salicylate (SA) or sodium caprylate (CA) as absorption-enhancing agents was investigated. Two types of hollow type suppositories were used--a conventional type (Type I) and a release-restricted type (Type II). Without SA or CA, GM was not absorbed. However, GM absorption was marked when 90 mg of solid SA or CA was added (the bioavailability of GM was 58% with SA, and 59% with CA). The enhancing effect of SA or CA (30 mg) in solid or aqueous solution form on GM absorption was evaluated using the Type I suppository. In the case of SA, the highest plasma GM level (Cmax 15.3 +/- 1.7 micrograms/ml, AUC0-4 27.3 +/- 3.9 h.micrograms/ml) was obtained following coadministration of powdered GM and SA; the plasma GM level (Cmax 1.5 +/- 0.6 micrograms/ml, AUC0-4 3.0 +/- 1.3 h.micrograms/ml) following the administration of a solution of GM and SA was significantly decreased as compared with the results using the powdered form. In the case of CA, the plasma GM level (Cmax 14.8 +/- 4.5 micrograms/ml, AUC0-4 25.4 +/- 8.7 h.micrograms/ml) following administration of the solution form was not significantly decreased in comparison with the results obtained using the powdered form. A marked increase in the enhancing effect of SA on the rectal GM absorption was found following use of Type II suppositories when GM and SA were coadministered in solution form. However, the GM absorption after coadministration of GM and CA using Type II suppositories was not significantly different from the absorption resulting from use of Type I suppositories. Our results suggest that the form and concentration of drug should not be ignored in evaluating the enhancing effects of SA or CA on the rectal absorption of poorly absorbed drugs such as GM.","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"4 3","pages":"247-56"},"PeriodicalIF":0.0,"publicationDate":"1989-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13636320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of C-terminal processing on the activity of human interferon-gamma. c端加工对人γ干扰素活性的影响。

Drug design and delivery Pub Date : 1989-05-01

T Arakawa, M A Narachi, Y R Hsu, R R Everett, P H Lai, E N Fish

{"title":"The effect of C-terminal processing on the activity of human interferon-gamma.","authors":"T Arakawa, M A Narachi, Y R Hsu, R R Everett, P H Lai, E N Fish","doi":"","DOIUrl":"","url":null,"abstract":"Homogeneous recombinant human interferon-gamma (IFN-gamma) obtained from Escherichia coli (E. coli) was treated with a protease-containing fraction prepared from mechanically lysed E. coli cells. Polyacrylamide gel electrophoresis of the resulting product revealed two major components of molecular weight less than that of intact IFN-gamma. These were purified by ion exchange chromatography in the presence of 7 M urea and shown to have intact IFN-gamma N-terminal sequences, suggesting that they resulted via C-terminal cleavages of IFN-gamma. Amino acid analysis indicated that 4 C-terminal residues of IFN-gamma were lacking in one, and 15 in the other. The species lacking 4 C-terminal residues had activities virtually indistinguishable from those of IFN-gamma in antiviral and growth inhibitory assays using Encepharomyocarditis-treated HeLa or T98G cells and in a macrophage activation assay using macrophage-like U937 cells. The species lacking 15 C-terminal residues had markedly decreased activities in each of these assays, and had decreased binding affinity for IFN-gamma cell surface receptors. These observations define the C-terminal residues important for IFN-gamma's biological activity--information which should be useful in designing analogs of IFN-gamma with enhanced or altered biological activities.","PeriodicalId":11271,"journal":{"name":"Drug design and delivery","volume":"4 3","pages":"217-25"},"PeriodicalIF":0.0,"publicationDate":"1989-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13665260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Markov process based model of the neurotransmitter-receptor binding process in the brain--comment. 大脑中神经递质-受体结合过程的马尔可夫过程模型——评论。

Drug design and delivery Pub Date : 1989-05-01

Z H Farooqi

引用次数: 0